Biocon has secured a license to introduce its Stelara biosimilar in nine additional countries, expanding treatment access for ...

Takeda Pharmaceutical aims for regulatory approval in Japan for its promising gastric cancer drug, TAK-921, following ...

AstraZeneca's late-stage trial data reveals significant improvements in overall survival for advanced stomach cancer patients using the drug sone-ve, outperforming chemotherapy and raising potential ...

The inclusion of Dr. Naresh Trehan in a pharmaceutical marketing review panel faces backlash from patient groups over ...

Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, has shown significant tumor shrinkage and reduced PSA levels ...

A groundbreaking study reveals that Amgen's Imdelltra, when combined with AstraZeneca's immunotherapy Imfinzi, significantly ...

Zymeworks has entered a global licensing agreement with Roche to develop and commercialize its experimental lung cancer drug ...

Kilitch Drugs has divested its Ethiopian subsidiary for $14 million, aiming to enhance its manufacturing capabilities in India and enter the lucrative GLP-1 market.

Bristol Myers Squibb reveals a patient death during an early-stage trial of its experimental CAR-T cell therapy for multiple ...

J.P. Morgan projects that the GLP-1 drug market in China, India, and Brazil could reach $22 billion by 2035, driven by ...

Speaking to reporters Dr Reddy’s Laboratories CEO, Erez Israeli said, the company plans to “relaunch” Obeda in Canada in Q3 and has also received approvals to launch the product in 10 other emerging ...